Utilidad del micofenolato de mofetilo en la nefritis lupica

Mofetil mycophenolate (MM) is an immunosuppressive agent that was initially used to prevent rejection in solid organ transplantation, and was later used to treat systemic autoimmune diseases. In Systemic Lupus Erythematosus (SLE) it was initially used for the treatment of Lupus Nephropathy (LN) and is now considered an important alternative agent for LN refractory to other drugs as well as in induction therapy with promising results and lower toxicity1-3. The first studies were limited to describing series with small numbers of patients where MM was used to treat patients with Cyclophosphamide (CF) and Azathioprine (AZA) resistant disease with favorable results. Subsequently several randomised studies have shown satisfactory results in the treatment of LN in both induction of remission and maintenance compared to the use of CF and AZA6-9. The good results obtained in the treatment of NL led to the MM being used for the treatment of other manifestations of the disease, such as vasculitis, neurological, skin, haematological and signs or symptoms of disease activity in general.